Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Consensus Recommendation of "Hold" by Brokerages

Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) have been assigned an average recommendation of "Hold" from the five research firms that are currently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $7.00.

A number of equities analysts have weighed in on the company. HC Wainwright upgraded Milestone Pharmaceuticals to a "buy" rating and set a $5.00 target price on the stock in a research note on Thursday, June 5th. Cowen lowered Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, April 1st. TD Securities lowered Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, April 1st. Finally, TD Cowen lowered Milestone Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, April 1st.

Hedge Funds Weigh In On Milestone Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Jones Financial Companies Lllp increased its position in shares of Milestone Pharmaceuticals by 1,000.0% during the 4th quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company's stock valued at $26,000 after purchasing an additional 10,000 shares during the last quarter. Bay Rivers Group bought a new position in Milestone Pharmaceuticals during the 2nd quarter worth approximately $28,000. National Bank of Canada FI grew its position in Milestone Pharmaceuticals by 163.4% during the 4th quarter. National Bank of Canada FI now owns 18,700 shares of the company's stock worth $44,000 after acquiring an additional 11,600 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in Milestone Pharmaceuticals during the 4th quarter worth approximately $73,000. Finally, XTX Topco Ltd bought a new position in Milestone Pharmaceuticals during the 4th quarter worth approximately $80,000. 86.18% of the stock is currently owned by institutional investors.

Milestone Pharmaceuticals Price Performance

MIST traded down $0.18 during trading on Friday, reaching $1.38. 6,991,150 shares of the company were exchanged, compared to its average volume of 1,086,334. The company's 50-day moving average is $1.65 and its two-hundred day moving average is $1.68. The company has a market cap of $73.77 million, a price-to-earnings ratio of -1.77 and a beta of 0.96. The company has a quick ratio of 4.67, a current ratio of 4.67 and a debt-to-equity ratio of 4.06. Milestone Pharmaceuticals has a 12-month low of $0.63 and a 12-month high of $2.75.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.12). Research analysts forecast that Milestone Pharmaceuticals will post -0.62 earnings per share for the current fiscal year.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.